Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic, developmental defect during embryogenesis disorder characterized by severe, early-onset, salt-wasting adrenal insufficiency and ambiguous/female external genitalia (irrespective of chromosomal sex) due to mutations in the <i>CYP11A1</i> gene. Milder cases may present delayed onset of adrenal gland dysfunction and genitalia phenotype may range from normal male to female in individuals with 46,XY karyotype. Imaging studies reveal hypoplastic/absent adrenal glands and biochemical findings include low serum cortisol, mineralocorticoids, androgens, and sodium, with elevated potassium levels.
Features include: Sex reversal, Increased circulating aldosterone concentration, Adrenocorticotropic hormone excess, and Hyperpigmentation of the skin and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 1 | Increased circulating aldosterone concentration |
Skin | 1 | Hyperpigmentation of the skin |
Hormones | 1 | Adrenal insufficiency |
Kidneys and urinary system | 1 | Renal salt wasting |
Muscles | 1 | Renal salt wasting |
CYP11A1 encodes cytochrome P450 family 11 subfamily A member 1 (521 aa). A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Highest expression in Adrenal Gland (1,056 TPM) and Ovary (68.9 TPM).
Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency is associated with mutations in the CYP11A1 gene on chromosome 15.
The CYP11A1 protein participates in CYP11A1 D271_V272insGD, CYP11A1 I279Yfs*10, and CYP11A1 mutants:FDXR:FDX1,FDX1L (red.) pathways.
CYP11A1 is classified as a druggable target (Cytochrome P450, Druggable Genome, and Enzyme categories) with score 4.4.
Genetic testing for CYP11A1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency.
107 publications have been identified in PubMed for Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency. Research spans Clinical Trial Publication (41%), Epidemiology / Natural History (36%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 44 | 41% |
Disease patterns and progression | 38 | 36% |
Testing and diagnosis research | 14 | 13% |
Patient case studies | 5 | 5% |
Laboratory research | 3 | 3% |
Other research | 1 | 1% |
Research summaries | 1 | 1% |
New treatment approaches | 1 | 1% |
Yu AJ (2026). [PMID: 41045292](https://pubmed.ncbi.nlm.nih.gov/41045292/). *International forum of allergy & rhinology*. [Diagnostic / Biomarker]
Poyrazoglu S (2026). [PMID: 41493898](https://pubmed.ncbi.nlm.nih.gov/41493898/). *Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation*. [Diagnostic / Biomarker]
AlAwadh SA (2026). [PMID: 42281707](https://pubmed.ncbi.nlm.nih.gov/42281707/). *Cureus*. [Diagnostic / Biomarker]
Lewis A (2026). [PMID: 41494697](https://pubmed.ncbi.nlm.nih.gov/41494697/). *BMJ open respiratory research*. [Clinical Trial Publication]
Milman B (2025). [PMID: 41522635](https://pubmed.ncbi.nlm.nih.gov/41522635/). *Journal of education & teaching in emergency medicine*. [Case Report / Case Series]
Barron E (2025). [PMID: 40931037](https://pubmed.ncbi.nlm.nih.gov/40931037/). *Nature medicine*. [Epidemiology / Natural History]
Dugan K (2025). [PMID: 40168025](https://pubmed.ncbi.nlm.nih.gov/40168025/). *JAMA network open*. [Epidemiology / Natural History]
Sugiyama K (2025). [PMID: 40658311](https://pubmed.ncbi.nlm.nih.gov/40658311/). *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*. [Clinical Trial Publication]
Mordal J (2025). [PMID: 40524244](https://pubmed.ncbi.nlm.nih.gov/40524244/). *Addiction science & clinical practice*. [Clinical Trial Publication]
Hodkiewicz VA (2025). [PMID: 40230466](https://pubmed.ncbi.nlm.nih.gov/40230466/). *Plastic and reconstructive surgery. Global open*. [Clinical Trial Publication]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:12 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Congenital adrenal insufficiency with 46, XY sex reversal OR 46,XY disorder of sex development-adrenal insufficiency due to CYP11A1 deficiency